I promise

"I promise, Suzy... Even if it takes the rest of my life." -Nancy G. Brinker, Founder of Susan G. Komen for the Cure

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Showing posts with label Genetic testing. Show all posts
Showing posts with label Genetic testing. Show all posts

Monday, April 27, 2015

YSC 2015 Part 1: Update on Triple Negative Breast Cancer

These are a few of the Informational PowerPoint slides on the latest on Triple Negative Breast Cancer and Heredity Breast Cancer that was presented at Young Survival Coalition Summit 2015 that I attended in Houston.


How your tumor responds to neoadjuvant chemo?
Androgen receptor positive for possible treatment target?
Androgen negative receptors = Quadruple Negative Breast Cancer?
Clinical trials of PARP inhibitors in TNBC  BRCA +
PARP inhibitors benefit TNBC BRCA positive patients
Immunotherapy  breast cancer vaccine on the horizon?
Breast cancer genes linked to other cancer related diseases
Why genetic testing is important?
Genetic testing for hereditary risk
Extra screenings or preventative surgery?

Friday, September 6, 2013

My Notes From a Genetic Testing Presentation

Recently, I went to a presentation on Genetic Testing and took some notes to share. I know that me having Triple Negative Breast Cancer and being diagnosed at under age 50, I have an increased risk of inheriting a BRCA1 or BRCA2 faulty gene. I have not been tested yet mainly because of financial reasons. I am learning more and more about heredity breast and ovarian cancers, and I'm coming to terms that "power of knowledge" can have an effect on my future health. I know how serious this is to get tested and to know one way or another so I can be proactive if there is a risk.

Heredity Breast and Ovarian Cancer (HBOC) syndrome is an inherited condition that causes an increased risk for ovarian, breast, pancreatic and prostrate cancer. The vast majority of hereditary breast and ovarian cancer is due to an alteration or gene mutation in either the BRCA1 or BRCA2 genes.  These genes mutations can be inherited from either your mother or father.



  • Sporadic Cancer- Occurs by chance
  • Familial Cancer- Not inherited. Combination of genetic and environmental risk factors.
  • Hereditary Cancer- Altered gene passed down from parent to child.





  • Genetics  

    Evaluate pedigree going back 3-4 generations:
     ❍ = Female, ❒ = Male



          ❍——————                             ————❍————
              Anna Keenan  ❙                              ❙                              ❙  Bertha 
          G. Grandmother  ❙                              ❙                              ❙  Great aunt
     Age 58, Lung Cancer ❙                              ❙                              ❙  Breast Cancer
                       ❍ ——— —                  ————❍                   ❍
                                          ❙                ❙  Hulda 
                                          ❙                ❙  Grandmother, 62
                                          ❙                ❙  Cancer of Spine/Tailbone, Buttocks
                           ❒——— ————————❍
               Joseph W. Stukenborg   ❙
                                Father, 59   
                                Melanoma   ❙
                                                 Melissa Paskvan (my profile)
                                                     Me, 41
                                                     Triple Negative Breast Cancer

    11-18% TNBC is BRCA Positive




    Who gets hereditary cancer testing? Having a significant family history of breast and/or ovarian cancer
    - Breast Cancer diagnosed before age 50
    - Ovarian Cancer
    - 2 breast cancers
    - Male breast cancer
    - Triple Negative Breast Cancer
    - Ashkenazi Jewish ancestry with heredity cancer
    - 3 or more hereditary cancers on one side of family
    - Previous hereditary mutation identified


    Genetic Counseling
    Follow-up Appointment- Must have referral
    1) Diagnosed under age 45

    2) Preventative - Have 2 or more Family History


    - Early 20's - Get genetic testing if heredity.
    or
    Additional screenings and treat as being positive until she gets tested.

     Children of diagnosed parent - Child should start screening at 10 years
    younger than parent's age at diagnosis.


    Testing
    • Blood test to determine if a woman is "highly susceptible" to breast and ovarian cancers.
    • Only way to identify gene mutation carriers of BRCA1 or BRCA2
    • Inform yourself on medical management decisions to reduce cancer risk
    • Determine family members risk
    • If gene mutation in immediate family, 50% chance of inheriting same gene mutation 

    BART    }  90 %
    BRCA1  }  Accurate


    Myriad - More reliable results
                 - Largest Data Base
                 - Testing since 1990's
                 - Less than 3% inaccuracy 
                 - Cost $4000
                 - 2 weeks test results 





    GINA - Genetic Information Non-Discrimination Act
               - Protects Employment and Health Insurance

    Bright Pink - The Little Bright Book A national non-profit organization providing education and support to young women who are at high risk for 
    breast and ovarian cancer. (Young 20-30's ladies trying to decide on pursuing testing)


    BRCA Positive Result options
    1. Increase Surveillance 
    • Monthly breast self exams at age 18, clinical breast exams twice a year at age 25
    • Yearly screening with both mammogram and MRI starting at age 25
    • Pelvic exam twice a year at age 35
    • Ovarian ultrasound and CA-125 levels in blood twice a year
    2. Medicine risk reduction
    • Tamoxifen reduce breast cancer risk up to 53%
    • Birth control pills reduce ovarian cancer risk up to 60%
    3. Preventative Surgery
    • Preventive mastectomy (breasts removal) reduce breast cancer risk up to 90%
    • Preventive Oophorectomy (ovaries and fallopian tubes removal) reduces risk of ovarian cancer up to 96% and breast cancer risk up to 68%

    USPSTF - Law for Affordable Care

    Qualify for 100% Coverage


    BRCA 1, Diagnosis Rate        \
    50-80% Breast Cancer           \
    40-60% 2nd Breast Cancer      \
    30-45% Ovarian Cancer             \
                                                         \      All Connected
                                                         /
    Colon Cancer                               /
    Pancreatic Cancer                      /
    Male Breast Cancer                  /
    Prostate Cancer                     /


    In May 2013, 37yr. old actress, Angelina Jolie, made a choice to have a preventative double mastectomy knowing she carried the BRCA1 gene.


    "For any woman reading this, I hope it helps you to know you have options," Jolie wrote. "I want to encourage every woman, especially if you have a family history of breast or ovarian cancer, to seek out the information and medical experts who can help you through this aspect of your life, and to make your own informed choices." - Angelina Jolie

    Wednesday, July 17, 2013

    Breast Cancer Gene Mutation

    Who should have genetic counseling and consider genetic testing for hereditary breast cancer?


    • A woman age 50 or younger who has been diagnosed with breast cancer.
    • A woman of any age of has had ovarian cancer or who has a first-degree* relative diagnosed with ovarian cancer.
    • Multiple breast or ovarian cancers (primary cancer) in a woman or a first degree relative.
    • Any individual with multiple family members with breast or ovarian cancer.
    • Any male with diagnosed breast cancer or individuals, male or female, with a family history of male breast cancer.
    • An individual with triple negative breast cancer at age 60 or younger; triple negative means the cancer cells lack certain biomarkers that make the cells responsive to treatment.
    • An individual of Ashkenazi Jewish heritage.
    *First-degree relatives include parents, siblings and children.
    Sources: National Comprehensive Cancer Network; and Melissa Dempsey, genetics counselor, Parkview Comprehensive Cancer Center

    http://www.news-sentinel.com/apps/pbcs.dll/article?AID=/20130702/NEWS/307029998/0/SEARCH (Click link to story)

    Three women share their stories
    http://www.news-sentinel.com/apps/pbcs.dll/article?AID=/20130703/NEWS/307039998 (Click link to story)





    Thursday, April 4, 2013

    The Ethical Implications of Gene Patenting

    "Do genes qualify as a property that a single individual or corporation is allowed exclusive rights to? This spring, the Supreme Court will hear a case that could dictate the future of biomedicine. Currently, Myriad Genetics Corporation, a biotechnology outfit in Utah, has patented two human genes known as BRCA1 and BRCA2. These genes are known to greatly elevate a woman's risk of breast and ovarian cancer. This patent allows Myriad Genetics to block all others from using these genes for the purposes of breast cancer diagnostics, research and treatment...."

    http://www.empowereddoctor.com/the-ethical-implications-of-gene-patenting (Click link to full story)

    UPDATE: Published June 13, 2013
    "Human genes may not be patented, the Supreme Court ruled unanimously on Thursday. The decision is likely to reduce the cost of genetic testing for some health risks, and it may discourage investment in some forms of genetic research.  The case concerned patents held by Myriad Genetics, a Utah company, on genes that correlate with an increased risk of hereditary breast and ovarian cancer."
    http://www.nytimes.com/2013/06/14/us/supreme-court-rules-human-genes-may-not-be-patented.html?_r=0 
    (Click link to story)

    Monday, April 1, 2013

    Breast Cancer Risk Genetic Testing Covered Under the Affordable Care Act?


    Today (March 6), Myriad Genetics, the company that makes the test for the breast cancer genes BRCA1 and BRCA2, said that the U.S. government considers these tests to be preventive services. This means that private insurance plans are required to cover the cost of the tests, including co-pays, deductibles and coinsurance, provided that the plans do not have a "grandfathered" status.
    http://www.myhealthnewsdaily.com/3590-genetic-testing-breast-cancer-insurance-coverage.html (Click to story)

    Total Pageviews



    "click image to link"